The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

• Status: Enrolling by invitation
• Trial end date: 2022-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study was search the safety and efficacy of the of Xiang Sha Liu Jun Zi Decoction (XSLJZ) in advanced hepatocellular carcinoma patients with multiple protein kinase inhibitor therapy. Evaluate the treatment effect on the symptoms of appetite and quality of life in advanced hepatocellular carcinoma patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: China Medical University Hospital

Criteria

Inclusion Criteria:

1. Advanced hepatocellular carcinoma patient

2. use multiple protein kinase inhibitor therapy paid by National Health Care Insurance system (NHCIS) in Taiwan

3. Child-Pugh A class

4. Eastern Cooperative Oncology Group performance status of 0-2

5. survival period over 3 months

6. used Xiang Sha Liu Jun Zi Decoction for one month before the multiple protein kinase inhibitor therapystarting point

Exclusion Criteria:

1. combine other cancer at the same time

2. ESRD under dialysis

3. heart disease,CHF、CAD、arrhythmia、hypertension (SBP>150mmHg，DSP>90 mmHg)

4. current serious infection

5. GI bleeding within 30 days

6. receive organ transplant

7. Child-Pugh Class B or C liver status。

8. Refractory Ascites in Liver Cirrhosis